Exploring The Therapeutic Potentials of Cannabigerolic Acid (CBGa); A Review

Daniel Gana, Chris Meleca, DJ Hill, Bob Hill
Life Research Co

INTRODUCTION

The interaction between cannabinoids and their receptors has been the bedrock of cannabis research and legalization efforts since 1964. At this time, approximately 70 countries have legalized the use of cannabis for medical or recreational purposes.

Neutral form or distillate-phytocannabinoids like CBD, CBC, CBN, CBG, and THC have been the subject of extensive research over the past 50 years. However, their acidic counterparts have remained largely unexamined. Most research papers dealing with cannabinoid acids like Cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), cannabichromenic acid (CBCA), and tetrahydrocannabinolic acid (THCA) have focused on their conversion to neutral cannabinoids with little focus on their therapeutic benefits when the acids are preserved, i.e., not decarboxylated. However the latest peer reviewed research has found cannabinoid acids to have potent therapeutic qualities beyond their neutral counterparts.

THERAPEUTIC POTENTIALS OF CBGA

CBGA recently made news as research from Oregon State confirmed its ability to prevent Covid-19 virions from infecting human cells. CBGA's "celebrity status" is long overdue. However, hundreds of studies have explored CBGA's antioxidant, anti-inflammatory, antimicrobial, anticonvulsant, anti-seizure, antidiabetic, neuroprotective, antidepressant, and anxiolytic properties.

Is CBGa **Proven** Self-Healing Medicine?

Get Full paper



What Does the Future Hold?

Rare cannabinoids like CBGA, CBG, CBGVA, CBDA, THCA, and CBCA are set to supplant CBD and THC as the new kid on the block in the near future. These rare cannabinoids, especially CBGA, possess an excellent therapeutic profile that outperforms CBD. CBGA research is still gaining steam, but studies consistently show a greater medicinal value than neutral cannabinoids. Perhaps most notably, research shows CBGA is more effective at calming seizures.

CBGA can also boost the activity of other cannabinoids while balancing the psychoactive effects of THC and other psychoactive cannabinoids. CBGA also has a greater dose response and may possess a higher bioavailability than CBD. That CBGA can produce better results than CBD at a lower dosage is nothing short of a breakthrough in cannabis medicine. Research is ongoing, but the future looks bright for CBGA and acidic cannabinoids.